Each uncoated bilayer tablet contains: Voglibose 0.2 MG + Metformin 500 MG + Glimepiride 2 MG
10X10 TABS (BLISTER PACK)
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications.
This is a combination of three antidiabetic medicines: Glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body’s sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents blood glucose from rising very high after meals.
SIDE EFFECTS :